Cargando…

Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer

BACKGROUND: Preclinical studies showed metformin reduces exhaustion of tumor-infiltrating lymphocytes and potentiates programmed cell death protein-1 (PD-1) blockade. We hypothesized that metformin with nivolumab would elicit potent antitumor and immune modulatory activity in metastatic microsatelli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akce, Mehmet, Farran, Batoul, Switchenko, Jeffrey M, Rupji, Manali, Kang, Sandra, Khalil, Lana, Ruggieri-Joyce, Amanda, Olson, Brian, Shaib, Walid L, Wu, Christina, Alese, Olatunji B, Diab, Maria, Lesinski, Gregory B, El-Rayes, Bassel F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603338/ https://www.ncbi.nlm.nih.gov/pubmed/37852737 http://dx.doi.org/10.1136/jitc-2023-007235

Ejemplares similares

Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer
por: Khalil, Lana, et al.
Publicado: (2022)

Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
por: Sahin, Ibrahim Halil, et al.
Publicado: (2019)

Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status
por: Akce, Mehmet, et al.
Publicado: (2021)

Predictive and Prognostic Effects of Primary Tumor Size on Colorectal Cancer Survival
por: Alese, Olatunji B., et al.
Publicado: (2021)

Role of local therapy in the management of patients with metastatic anal squamous cell carcinoma: a National Cancer Database study
por: Atallah, Rami P., et al.
Publicado: (2022)

Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma
por: Zakka, Katerina, et al.
Publicado: (2019)

High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer
por: Mohamed, Amr, et al.
Publicado: (2021)

Blood-based next-generation sequencing analysis of neuroendocrine neoplasms
por: Zakka, Katerina, et al.
Publicado: (2020)

Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States
por: Alese, Olatunji B., et al.
Publicado: (2015)

P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
por: Fedorova, Liudmila, et al.
Publicado: (2022)

IMMU-26. DISEASE CONTROL IN A PEDIATRIC PATIENT WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) AND SOMATIC HIGH MICROSATELLITE INSTABILITY (MSI-H) WITH PD-1 INHIBITOR NIVOLUMAB (NIVO) ONLY AND NO FOCAL RADIOTHERAPY (RT)
por: Larkin, Trisha, et al.
Publicado: (2020)

Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer
por: Bando, Hideaki, et al.
Publicado: (2022)

IMMU-09. NIVOLUMAB THERAPY FOR A PEDIATRIC-ONSET PRIMARY INTRACRANIAL MELANOMA
por: Oba, Utako, et al.
Publicado: (2020)

The Potential of CAR T Cell Therapy in Pancreatic Cancer
por: Akce, Mehmet, et al.
Publicado: (2018)

P062: The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma
por: Fedorova, Liudmila, et al.
Publicado: (2022)

HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy
por: Nagaraju, Ganji Purnachandra, et al.
Publicado: (2014)

Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology
por: Kang, Sandra Mirie, et al.
Publicado: (2022)

Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival
por: Shah, Manish A, et al.
Publicado: (2021)

Soluble PD-L1 as an early marker of progressive disease on nivolumab
por: Mahoney, Kathleen M, et al.
Publicado: (2022)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
por: He, Jie, et al.
Publicado: (2023)

Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers
por: Kang, Sandra, et al.
Publicado: (2022)

Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy
por: Bilen, Mehmet Asim, et al.
Publicado: (2019)

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
por: Motzer, Robert J, et al.
Publicado: (2022)

Correlation Patterns Among B7 Family Ligands and Tryptophan Degrading Enzymes in Hepatocellular Carcinoma
por: Chinnadurai, Raghavan, et al.
Publicado: (2020)

Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
por: Fukuda, Shohei, et al.
Publicado: (2021)

Plasma-based microsatellite instability detection strategy to guide immune checkpoint blockade treatment
por: Wang, Zhenghang, et al.
Publicado: (2020)

Frontline therapy for advanced hepatocellular carcinoma: an update
por: Akce, Mehmet, et al.
Publicado: (2022)

Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
por: Das, Anirban, et al.
Publicado: (2023)

In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies
por: Ieranò, Caterina, et al.
Publicado: (2022)

A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
por: Taniguchi, Yuri, et al.
Publicado: (2022)

T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma
por: Wang, Xuefeng, et al.
Publicado: (2022)

Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis
por: Mallardo, Domenico, et al.
Publicado: (2022)

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
por: Cohen, Romain, et al.
Publicado: (2020)

A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
por: Owen, Dwight H., et al.
Publicado: (2023)

Predictive value of integrated (18)F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer
por: Umeda, Yukihiro, et al.
Publicado: (2020)

Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer
por: Ware, Michael Brandon, et al.
Publicado: (2020)

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors
por: Lemech, Charlotte, et al.
Publicado: (2023)

Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
por: Hanna, Glenn J., et al.
Publicado: (2022)

Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target
por: Wang, Haizhou, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fb0emamqc5r8b5c15o9q914670